Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

114.00 -0.32 (-0.28%)
Streaming Delayed Price Updated: 1:16 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 596,217
Open 113.98
Bid (Size) 113.97 (9)
Ask (Size) 114.00 (1)
Prev. Close 114.32
Today's Range 113.75 - 114.27
52wk Range 92.19 - 120.92
Shares Outstanding N/A
Dividend Yield 3.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European... 
Via Benzinga

Performance

YTD
+12.87%
+12.87%
1 Month
-2.04%
-2.04%
3 Month
+5.85%
+5.85%
6 Month
+17.19%
+17.19%
1 Year
+20.39%
+20.39%

More News

Read More
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Via The Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
Via Benzinga
Looking Into Novartis's Recent Short Interest
Via Benzinga
Why NYSE:NVS is a Top Pick for Dividend Investors.
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Via Chartmill
2 Magnificent Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm
Via Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
Via Investor's Business Daily
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Via Benzinga
Topics Economy
Exposures Interest Rates
The Importance of Managing Bad Cholesterol: What You Should Know
Via Brandpoint
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Via FinancialNewsMedia
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Via Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.